152 related articles for article (PubMed ID: 17296587)
1. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.
Arkenau HT; Chong G; Cunningham D; Watkins D; Sirohi B; Chau I; Wotherspoon A; Norman A; Horwich A; Matutes E
Haematologica; 2007 Feb; 92(2):271-2. PubMed ID: 17296587
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Chau I; Harries M; Cunningham D; Hill M; Ross PJ; Archer CD; Norman AR; Wotherspoon A; Koh DM; Gill K; Uzzell M; Prior Y; Catovsky D
Br J Haematol; 2003 Mar; 120(6):970-7. PubMed ID: 12648066
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
Mahadevan D; Unger JM; Spier CM; Persky DO; Young F; LeBlanc M; Fisher RI; Miller TP
Cancer; 2013 Jan; 119(2):371-9. PubMed ID: 22833464
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
Ng M; Waters J; Cunningham D; Chau I; Horwich A; Hill M; Norman AR; Wotherspoon A; Catovsky D
Br J Cancer; 2005 Apr; 92(8):1352-7. PubMed ID: 15812553
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
[TBL] [Abstract][Full Text] [Related]
6. Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma.
Yim KL; Ashley S
Med Oncol; 2012 Dec; 29(5):3535-9. PubMed ID: 22825684
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).
Sirohi B; Cunningham D; Norman A; Last K; Chau I; Horwich A; Oates J; Chong G; Wotherspoon A
Hematology; 2007 Apr; 12(2):149-53. PubMed ID: 17454196
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
Dong M; He XH; Liu P; Qin Y; Yang JL; Zhou SY; Yang S; Zhang CG; Gui L; Zhou LQ; Shi YK
Med Oncol; 2013 Mar; 30(1):351. PubMed ID: 23269584
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China.
Zhang Y; Zhang W; Li J; Duan M; Han B; Zhu T; Zhuang J; Cai H; Cao X; Chen M; Zhou D
Ann Hematol; 2019 Jan; 98(1):143-150. PubMed ID: 30209556
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
Li L; Duan W; Zhang L; Li X; Fu X; Wang X; Wu J; Sun Z; Zhang X; Chang Y; Nan F; Yan J; Li Z; Young KH; Zhang M
Br J Haematol; 2017 Sep; 178(5):772-780. PubMed ID: 28597542
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
12. [Gemcitabine combined with cisplatin and methylprednisolone sodium succinate in chemotherapy for relapsed or refractory T cell non-Hodgkin lymphoma].
Zhao S; Zhang QY; Sun WZ
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):316. PubMed ID: 20510089
[No Abstract] [Full Text] [Related]
13. Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin Therapy in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Study Protocol.
Yamasaki S; Kada A; Nagai H; Yoshida I; Choi I; Saito AM; Iwasaki H
Acta Med Okayama; 2019 Oct; 73(5):469-474. PubMed ID: 31649375
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma.
Yang SH; Lin ZZ; Kuo SH; Cheng AL
Am J Hematol; 2009 Jul; 84(7):457-9. PubMed ID: 19484737
[No Abstract] [Full Text] [Related]
15. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
Zinzani PL; Magagnoli M; Bendandi M; Orcioni GF; Gherlinzoni F; Albertini P; Pileri SA; Tura S
Ann Oncol; 1998 Dec; 9(12):1351-3. PubMed ID: 9932168
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
Evens AM; Rosen ST; Helenowski I; Kline J; Larsen A; Colvin J; Winter JN; van Besien KM; Gordon LI; Smith SM
Br J Haematol; 2013 Oct; 163(1):55-61. PubMed ID: 23927371
[TBL] [Abstract][Full Text] [Related]
17. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
[TBL] [Abstract][Full Text] [Related]
18. [A case of refractory pulmonary peripheral T cell lymphoma successfully treated with Cisplatin Plus Gemcitabine Plus Solumedrol].
Uemura Y; Imai T; Nakajim T; Urata T; Doi H
Nihon Kokyuki Gakkai Zasshi; 2010 Jan; 48(1):28-32. PubMed ID: 20163018
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder.
Malik IA; Aziz Z; Zaidi SH; Sethuraman G
Am J Clin Oncol; 2003 Apr; 26(2):174-7. PubMed ID: 12714891
[TBL] [Abstract][Full Text] [Related]
20. Pralatrexate Induces Long-Term Remission in Relapsed Subcutaneous Panniculitis-Like T-Cell Lymphoma.
Ong SY; Phipps C; Kaur H; Tan L; Lee YS
Ann Acad Med Singap; 2019 Sep; 48(9):298-300. PubMed ID: 31737895
[No Abstract] [Full Text] [Related]
[Next] [New Search]
